Feed CRNX
CR

Crinetics CRNX · NASDAQ

$84.95 -0.01% (-$0.01)

Market cap
$9.00B
Enterprise value
$8.99B
P/E
-
Forward P/E
-
PEG
-
P/S
213.5x
P/FCF
-
EV/EBITDA
-
ROIC
-44.0%
Gross margin
99.2%
Net margin
-1,189.9%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
0.13
Free float
93.7%

About the company

Crinetics Pharmaceuticals, Inc. is a biotechnology company focused on developing therapeutics for the treatment of endocrine and metabolic disorders. The company specializes in discovering and developing new drugs that modulate G-protein-coupled receptors, which are key mechanisms for regulating hormonal signaling in the body. Crinetics focuses on developing treatments for diseases such as acromegaly (caused by excessive growth hormone secretion), Cushing’s disease, and other hormonal disorders. The company's goal is to provide innovative treatment options for patients with these rare conditions.

Sector

Healthcare

Industry

Biotechnology

CEO

R. Scott Struthers

Employees

594

Headquarters

San Diego

Valuation

Is today's price reasonable?

  • What to watch: The share price is above the Bulios Fair Price.

Growth and estimates

Is it growing, and what comes next?

  • What speaks for it: Revenue grew by 18% a year over the last 3 years.
  • What to watch: It missed profit estimates 5 times in the last 8 quarters.

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

  • What to watch: The company made a loss over the last 12 months.

Financial health

Can it carry its debt?

  • What speaks for it: It holds more cash than debt: $55.5M against $47.2M.
  • What to watch: It passes only 2 of the 9 points of the Piotroski financial health test.

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy